Journal Article Summary
The article examines a new formulation of aspirin called phospholipid-aspirin complex (PL-ASA), which aims to improve the safety and effectiveness of aspirin therapy. Aspirin is widely used to prevent recurrent cardiovascular events, but traditional formulations can cause gastrointestinal (GI) issues and have unpredictable absorption rates. The study highlights the need for a formulation that minimizes these risks while maintaining reliable antiplatelet effects, which are crucial for patients with atherosclerotic disease.
In the study, researchers compared PL-ASA with traditional plain aspirin and enteric-coated aspirin in terms of how well they are absorbed and their effects on platelet function. They found that PL-ASA resulted in significantly lower rates of acute GI injury, such as erosions and ulcers, compared to plain aspirin. Additionally, PL-ASA demonstrated predictable absorption and effective platelet inhibition, making it a promising alternative to existing aspirin formulations, particularly for patients who may experience complications from traditional aspirin use.
However, the study has limitations, including a focus on short-term effects and a lack of data on long-term safety, especially regarding GI health. Patients should consult their healthcare providers about the potential benefits and risks of switching to PL-ASA, particularly if they have experienced GI issues with other aspirin formulations. Ongoing research is needed to fully understand the long-term implications of using PL-ASA and its effectiveness compared to standard treatments.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Angiolillo Dominick J., Prats Jayne, Deliargyris Efthymios N., Schneider David J, Scheiman James, Kimmelstiel Carey, Steg Ph. Gabriel, Alberts Mark, et al.. Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. Clinical Pharmacokinetics 2022. DOI: 10.1007/s40262-021-01090-2. PMID: 35060092. PMCID: PMC8773391.
Featured Pill Pals Product
OTC 1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
